Variant Philadelphia translocations with different breakpoints in six chronic myeloid leukemia patients / Alti kronik miyeloid losemi olgusunda farkli kirik noktali varyant Philadelphia translokasyonlari.
Chronic myeloid leukemia
(Development and progression)
Cancer (Care and treatment)
Arguden, Yelda Tarkan
Ar, Muhlis Cem
Eskazan, Ahmet Emre
|Publication:||Name: Turkish Journal of Hematology Publisher: Aves Yayincilik Audience: Academic Format: Magazine/Journal Subject: Health Copyright: COPYRIGHT 2011 Aves Yayincilik ISSN: 1300-7777|
|Issue:||Date: Sept, 2011 Source Volume: 28 Source Issue: 3|
|Product:||Product Code: 8000432 Cancer Therapy NAICS Code: 621 Ambulatory Health Care Services|
Objective: The Philadelphia (Ph) chromosome, consisting of the t(9;22)(q34;q11) translocation, is observed in--90% of patients with chronic myeloid leukemia (CML). Variant Ph translocations are observed in 5%-10% of CML patients. In variant translocations 3 and possibly more chromosomes are involved. Herein we report 6 CML patients with variant Ph translocations.
Materials and Methods: Bone marrow samples were examined using conventional cytogenetic meth ods. Fluorescence in situ hybridization (FISH) with whole-chromosome paints and BCR-ABL 1D probes were used to confirm and/or complement the findings, and identify rearrangements beyond the resolution of conventional cytogenetic methods.
Results: Variant Ph translocations in the 6 patients were as follows: t(7;22)(p22;q11), t(9;22;15) (q34;q11;q22), t(15;22)(p11;q11), t(1;9;22;3)(q24;q34;q11;q21), t(12;22)(p13;q11), and t(4;8;9;22) (q11;q13;q34;q11).
Conclusion: Among the patients, 3 had simple and 3 had complex variant Ph translocations. Two of the presented cases had variant Ph chromosomes not previously described, 1 of which had a new complex Ph translocation involving chromosomes 1, 3, 9, 22, and t(1;9;22;3)(q24;q34;q11;q21) apart from a clone with a classical Ph, and the other case had variant Ph translocation with chromosomes 4, 8, 9, and 22, and t(4;8;9;22)(q11;q13;q34;q11) full complex translocation. Number of studies reported that some patients with variant Ph translocation were poor responders to imatinib. All of our patients with variant Ph translocations had suboptimal responses to imatinib, denoting a poor prognosis also. ariant Ph translocations may be important as they are associated with prognosis and therapy for CML patients. (Turk J Hematol 2011; 28: 186-92)
Key words: Chronic myeloid leukemia (CML), variant Ph chromosome, cytogenetics, fluorescence in situ hybridization (FISH)
Received: June 25, 2010
Accepted: August 19, 2010
Amac: t(9;22)(q34;q11) sonucu olusan Philadelphia (Ph) kromozomu, kronik miyeloid losemi (KML) olgularinin %90' dan fazlasinda gozlenir. KML hastalarinin %5-10 unda varyant Ph translokasyonlari bulunur. Varyant translokasyonlar uc ve daha fazla kromozom icerebilmektedir. Bu calismada varyant Ph translokasyonlu 6 KML olgusu sunulmaktadir.
Yontemler ve Gerecler: Kemik iligi ornekleri konvansiyonel sitogenetik kullanilarak incelendi; BCR-ABL 1D problarinin kullamldigi Floresan In Situ Hibridizasyon (FISH) yontemi bulgularin dogrulan-masi ve konvansiyonel sitogenetik yontemlerinin tespit etmekte yetersiz kaldigi yeniden duzenlemele-rin tanimlanmasi amaciyla uygulandi.
Bulgular: calismada yer alan 6 hastanin varyant Ph translokasyonlari: t(7;22)(p22;q11), t(9;22;15) (q34;q11;q22), t(15;22)(p11;q11), t(1;9;22;3)(q24;q34;q11;q21), t(12;22)(p13;q11) ve t(4;8;9;22) (q11;q13;q34;q11) dir.
Sonuc: Uc olguda bash, 3 olguda ise karmasik (kompleks) varyant Ph translokasyonlari saptaims bulunuyoruz. Olgularimizin ikisi daha once bildirilmeyen varyant Ph kromozomlari tasiyorlardi. Bu olgulardan biri klasik Ph'li bir klonun yanisira 1, 9, 22 ve 3 numarahli kromozomlari iceren t(1;9;22;3) (q24;q34;q11;q21) formullu yeni bir kompleks Ph translokasyonuna; digeri ise 4, 8, 9 ve 22 numarah kromozomlari iceren t(4;8;9,22)(q11;q13;q34;q11) kompleks translokasyonlu varyant Ph'ya sahipti-ler. Varyant Ph'li 6 olgunun tumu kotu prognoza isaret eden yetersiz imatinib cevabi gosterdiler. (Turk J Hematol 2011; 28: 186-92)
Anahtar kelimeler: Kronik myeloid losemi (KML), varyant Philadelphia kromozomu, sitogenetik, floresan in situ hibridizasyon (FISH)
Gelis tarihi: 25 Haziran 2010
Kabul tarihi: 19 Agustos 2010
Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasm arising from neoplastic transformation of a pluripotent stem cell. The Philadelphia (Ph) chromosome, which is the result of t(9;22)(q34;q11), is observed in ~90% of CML patients. The translocation leads to fusion of the proto-oncogene Abelson (ABL) and a particular DNA sequence known as breakpoint cluster region (BCR), thereby giving rise to 2 new chimeric genes 5' ABL-3' BCR on the derivative chromosome 9 and 5' BCR-3' ABL on the derivative chromosome 22. Variant Ph translocations have been observed in 5%-10% of CML patients (1). These variant translocations may be simple or complex. Simple variant translocations occur when the deleted segment of 22q is translocated onto a chromosome other than chromosome 9. In complex translocations, 3 and possibly more chromosomes are involved (2), (3). In a few cases of variant Ph translocations the BCR-ABL fusion gene is located on chromosomal sites other than 22q11 (4).
More than 1 mechanism plays a role in the evolution of variant Ph translocation; it can originate secondary to simple Ph translocation or can arise simul-taneously in a 3-way rearrangement. Different mechanisms involved in the formation of a variant translocation may have different clinical implications: a 2-step evolution might resemble a clonal evolution, whereas variant translocations that evolve simultaneously in a 3-way rearrangement may be similar to simple Ph translocation (5). The clinical significance of variant t(9;22) translocations is not clear (4).
In the present study bone marrow samples from 6 CML patients were examined using conventional cytogenetic methods, FISH with whole-chromo-some paints, and BCR-ABL 1 D probes to confirm and/or complement the findings, and identify rear-angements beyond the resolution of conventional cytogenetic methods. Additionally, 2 of the CML patients had new complex translocations; 1 between chromosomes 1, 3, 9, 22, and other between 4, 8, 9, and 22. Possible correlations between chromosome breakpoints other than 9 and 22 in these Ph variant tranlocations, and recent updates for the map locations of consistent cancer breakpoints, fragile sites, and oncogenes are discussed.
Materials and Methods
The study included 6 clinically diagnosed CML patients that were referred for cytogenetic analysis and had variant Ph translocations. Clinical features of the patients are shown in Table 1.
Cytogenetic and FISH analysis
Bone marrow (BM) samples were used for cytogenetic and FISH analysis.
Cytogenetic analysis was performed on overnight and 24-h unstimulated BM cultures using standard procedures. The GTL (G-bands via trypsin using Leishman) banding technique (6) was applied to the slides, karyotypes were described according to the International System for Human Cytogenetic Nomenclature (2005) (7), and 15-20 metaphases were analyzed for each sample.
Fresh slides were used for FISH analysis. Before hybridization the slides were pretreated with pepsin, followed by post-fixation and denaturation. FISH analysis was performed according to the manufacturer's protocols. BCR-ABL1 rearrangement was examined using a BCR-ABL1 D-FISH probe (BCR: 500 Kb in red; ABL1: 600 Kb in green; Oncor, Inc., Gaithersburg, MD, USA).
FISH analyses using whole chromosome paint (WCP) probes to characterize only complex variant translocations in patients 2, 4 and 6.: for patient 2 painting probes for chromosomes 15 and 22 were digoxigenin labeled (WCP 15 and WCP 22; Oncor, Gaithersburg, MD, USA); for patient 4 painting probes for chromosomes 1, 9, and 22 (WCP 1, 9, and 22; XCP-MetaSystems); for patient 6 painting probes for chromosomes 4, 8, 9, and 22 (WCP 4, 8, 9, and 22; XCP-MetaSystems and Cytocell). Fluorescence microscopy was performed with a Nikon E600 microscope with a tri-ple-pass filter and a cooled monochrome CCD camera, using MacProbe FISH analysis software and a CytoVision Ultra system (Applied Imaging, Pittsburgh, PA).
Variant Ph translocations were identified in all 6 patients using G-banding analysis, and were confirmed via FISH analysis. G-banding and FISH results are shown in Table 2.
In all, 3 of the patients (1, 3, and 5) had simple variant Ph translocations and 3 (2, 4, and 6) had complex translocations. Among the complex variant Ph translocations, 3 chromosomes were involved in 1 patient (2) and 4 chromosomes were involved in 2 patients (4 and 6). Clonal evolution was observed only in patient 4; there were 2 clones 1 with a classical Ph and 1 with t(1;9;22,3) (q24;q34;q11;q21). The chromosomal breakpoints of the variant Ph translocations were 1 q24, 3q21, 4q11, 7p22, 8q13, 12p13,15p11, and 15q22. In patient 3 additional clonal chromosomal changes along with variant Ph translocation were observed [t(13,15) (p11;q13)]. Partial G-banding karyotypes are presented in Figure 1.
[FIGURE 1 OMITTED]
In 5 patients (1, 3, 4, 5, and 6) dual-color FISH with the use of the BCR and ABL probes showed the BCR-ABL fusion gene on the Ph chromosome. In patient 2 BCR and ABL probes could not be used due to insufficient material. With the WCP probes involvement of chromosomes other than 9 and 22 in the complex variant translocations were confirmed in patients 2, 4, and 6. FISH images are shown in Figure 2.
[FIGURE 2 OMITTED]
In the present study chromosomal breakpoints of the variant Ph translocations other than classical 9 and 22 breakpoints were 1q24, 3q21, 4q11, 7p22, 8q13, 12p13,15p11, and 15q22. All 8 breakpoints observed in the 6 patients are listed as variant Ph translocations in the Mitelman database (http://www.cgap.nci.nih.gov/Chromosomes/Mitelman; updated 23 February 2009) (8). Among the chromosomes that constituted variant Ph translocations in the presented patients, those that were previously described are shown in Table 3.
It was reported that breakpoints involved in variant Ph translocations are primarily located in light-staining bands (2). Apart from 1q24, the breakpoints observed in the present study were also in light-staining bands. Most of the breakpoints observed in the present study harbor genes known to be associ--ated with neoplasia. GPA33 in 1q24, DIRC2 and HSPBAP1 in 3q21, BTL in 4q11, ETV6 in 12p13, and PML in 15q22 genes are implicated in different leukemias and solid tumors, but the gene in 8q13 is unknown (20). Band 7p22 in patient 1 corresponded to the map location of common fragile sites (21).
Among the 6 presented patients, 3 had simple and 3 had complex variant Ph translocations. To the best of our knowledge only a few cases of variant Ph translocations involving > 3 chromosomes have been reported [1,5,9,11-19,22,231. In all, 2 of the presented patients (4 and 6) had 4-way rearrangement [t(1;9,22;3)(q24;q34;q11;q21) and t(4;8;9;22) (q11;q13;q34;q11)], including breakpoints that differed from those previously reported. CML studies reported 1q24 and 3q21 in simple and 3-way variant Ph translocations (8), (20). The literature does not contain any reports of 4-way complex translocations involving the chromosomal band 1 q24 in CML patients. Similarly, simple and complex variant Ph translocations involving chromosomal bands 4q11 and 8q13 have not yet been reported in CML patients. In CML patients 8q13 has been reported in translocations other than Ph and 4q 11 was reported in association with ANLL (8), (18), (20). Specific chromosomal abnormalities involving band 3q21 have been observed in all FAB subtypes of acute myeloid leukemia (AML), in myelodysplastic syndrome, occasionally in the blastic phase of chronic myeloid leukemia, and rarely in chronic phase CML.
In some older studies variant Ph translocations involving 3q21 were considered a marker of poor prognosis in CML, and were used to justify the necessity of increasing the dose of imatinib, as commonly administered in the accelerated phase (24). Patient 4 in the present study did not have a hematological or cytogenetic response to imatinib. Consequently, imatinib was replaced by dasatinib, which was administered for 1 year, but also did not result in a cytogenetic or hematological response. Excluding patient 3, all the presented patients with variant Ph translocations were poor responders to imatinib and were therefore treated with dasatinib.
The strongest evidence for serial stepwise rearrangements resulting in variant Ph translocation comes from the rare observation of patients with a standard Ph in 1 clone and a complex variant Ph in another clone, as in patient 4 in the present study, who had 1 clone with t(9;22)(q34;q11) and 1 clone with a complex variant Ph translocation t(1,9,22;3)(q24;q34;q11;q21). Cytogenetic evidence suggests that complex Ph translocation is derived from simple Ph translocation (17), (25).
The breakpoints of variant Ph translocations in CML patients may be important, as they are associated with carcinogenesis. Above all, monitorization of chromosomes and localization of precise breakpoints involved in the complex rearrangements in CML patients will improve our understanding of the genetic mechanisms that play a role in the progression of malignant disease. We trust that the present study's results will contribute to the scientific community's knowledge of CML cytogenetics. Written informed consent was obtained from all the patients.
Conflict of interest statement
The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.
(1.) Aoun P, Pickering D, Foran J, Rasheed H, Wiggins M, Pavletic SZ, Sanger W. Interphase fluorescence in situ hybridization studies for the detection of 9q34 deletions in chronic myelogenous leukemia: a practical approach to clinical diagnosis. Cancer Genet Cytogenet 2004;154:138-43.
(2.) Stopera SA, Ray NI, Riordan D, Christie N, Wickstrom D. Variant Philadelphia translocations in chronic myeloid leukemia: correlation with cancer breakpoints, fragil sites and oncogenes. Cancer Lett 55:249-53.
(3.) Lazarevic V, Jankovic G, Kraguljac N, Djordjevic V, Miljic P, Bogunovic M, Rajic Z, Cemerikic-Martinovic V, Suvajdzic N, Colovic M. Clinical, Immunophenotypic and Cytogenetic Features of Megakaryocytic Blast Crisis of Chronic Myeloid Leukemia: A Single Institution Study. Turk J Haematol 2001;18:107-15.
(4.) Zagaria A, Anelli L, Albano F. A fluorescence in situ hybridization study of complex t(9;22)(q34;q11) in two chronic myeloid leukemia cases with in a masked Philadelphia choromosome. Cancer Genet Cytogenet 2004;150:81-5.
(5.) Yehuda 0, Abeliovich D, Ben-Neriah S, Sverdlin I, Cohen R, Varadi G et al. Clinical implications of Fluorescence In Situ Hybridization Analysis in 13 Chronic Myeloid Leukemia Cases: Ph-Negative and Variant Ph-positive. Cancer Genet Cytogenet 1999;114:100-7.
(6.) Yunis J. Comparative analysis of high resolution chromosome techniques for leukemia bone marrows. Cancer Genet Cytogenet 1982;7:43-50.
(7.) Shaffer LG, Tommerup N. (eds) ISCN: An International system for Human Cytogenetic Nomenclature International Standing Committee on Human Cytogenetic Nomenclature. In: Neoplasia, Basel: S. Karger, 2005. pp. 88-95.
(8.) Mitelman F, Johansson B, Mertens F. Mitelman database of chromosome aberrations in cancer. Available from: http://www.cgap.nci.nih.gov/Chromosomes/Mitelman. Accessed 23 February 2009.
(9.) Acar H, Stewart J, Boyd E, Connor MJ. Identification of Variant Translocations in Chronic Myeloid Leukemia by Fluorescence In Situ Hybridization. Cancer Genet Cytogenet 1997;93:115-8.
(10.) Morel F, Herry A, Le Bris MJ. Contribution of fluores-cence in situ hybridization analyses to the character-ization of masked and complex Philadelphia chromo-some translocations in chronic myelocytic leukemia.
Cancer Genet Cytogenet 2003;147:115-20.
(11.) Zagariaa A, Anellia L, Albanob F, Vicaric L, Schiavoned E M, Annunziatad M et al. Molecular cytogenetic characterization of deletions on der(9) in chronic myelocytic leukemia. Cancer Genet Cytogenet 2006;167:97-102.
(12.) Zhang J, Meltzer P, Jenkins R, Guan X-Y, Trent J. Application of Chromosome Microdissection Probes for Elucidation BCR-ABL Fusion and Variant Philadelphia Chromosome Translocations of in Chronic Myelogenous Leukemia. Blood 1993;81:3365-71.
(13.) Reddy KS, Sulcova V. A FISH Study of Variant Philadelphia Rearrangements. Cancer Genet Cytogenet 2000;118:121-31.
(14.) Costa D, Carrio A, Madrigal I, Arias A, Valera A, Colomer D et al. Studies of complex Ph translocations in cases with chronic myelogenous leukemia and one with acute lymphoblastic leukemia. Cancer Genet Cytogenet 2006;166:89-93.
(15.) Markovic VD, Bouman D, Bayani J, Al-Maghrabi J, Kamel-Reid 3, Squire JA. Lack of BCR/ABL reciprocal fusion in variant Philadelphia chromosome translocations: a use of double fusion signal FISH and spectral karyotyping. Leukemia 2000;14:1157-60.
(16.) Babicka L, Pavlistova L, Brezinova J, Zemanova Z, Ransdorfova S, Houskova L. Complex chromosomal rearrangements in patients with chronic myeloid leukemia. Cancer Genet Cytogenet 2006;168:22-9.
(17.) Reid AG, Huntly BJP, Grace C, Green AR, Nacheval EP. Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia. Br J Haematol 2003;121:19-27.
(18.) Baxter EJ, Hochhaus A, Bolufer P, Reiter A, Senent L, Cervera J, Moscardo et al. The t(4;22)(q12;q11) in atypical hronic myeloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet 2002;11:1391-7.
(19.) Sheth F J, Sheth JJ, Verhest A. A three way complex translocation (4;9;22) in two patients with chronic myelocytic leukemia. J Cancer Res Ther 2005;1:108-10 (BRIEF COMMUNICATIONS),
(20.) Atlas of Genetics and Cytogenetics in Oncology and Haematology. Available from: URL http://AtlasGeneticsOncology.org/
(21.) Huret JL, Tanzer J, Henry-Amar M. Aberrant breakpoints in chronic myelogenous leukemia; oncogenes and fragile sites. Hum Genet 1986;74:447-8.
(22.) Sessarego M, Fugazza C. Bruzzone R, Ballestrero A, Miglino M, Bacigalupo A. Complex chromosome rearrangements may locate the bcr/abl fusion gene sites other 22q11. Haematologica 2000;85:35-9.
(23.) Reid A, Gribble SM, Huntly BJP, Andrews KM, Campbell L, Grace CD. Variant Philadelphia translocations in chronic myeloid leukaemia can mimic tpycal blastic crisis chromosome abnormalities or classic t(9;22): a report of two cases. Br J Haematol 2001;113:439-42.
(24.) Buda G, Orciuolo E, Galimberti S, Benedetti E, Caracciolo F, Cervetti G, Carulli G, Papineschi F, Petrini M. Complex translocation t(3;9;22)(q21;q34;q11) at diagnosis is a negative prognostic index in chronic myeloid leukemia. Leuk Res 2000;32:192-4.
(25.) Juan PME, Cardenas VJP, Jimenez EAV, Angulo MG, Flores MAE, Garcia JRG. A complex translocation (9,22,16)(q34;q11.2;p13) in chronic myelocytic leukemia. Cancer Genet Cytogenet 2005;157:175-7.
Dilhan Kuru (1), Yelda Tarkan Arguden (1), Muhlis Cem Ar (3), Ayse Cirakoglu (1), Seniz Ongoren (3), Sukriye Yilmaz (1), Ahmet Emre Eskazan (3), Ayhan Deviren (2), Teoman Soysal (3), Seniha Hacihanefloglu (2), Birsen Ulku (3)
(1) Department of Medical Biology, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
(2) Department of Medical Genetics, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
(3) Department of Internal Medicine, Division of Hematology, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
Address for Correspondence: Dr. Dilhan Kuru, Department of Medical Biology, Cerrahpas Faculty of Medicine, Istanbul University, Istanbul, Turkey Phone: +90 212 414 30 34 E-mail: email@example.com
Table 1. Clinical features of the patients Case 1 2 3 4 5 6 Age/Sex 39/F 23/M 52/M 33/F 60/F 32/M Reason for referral CML CML CML CML CML CML Splenomegaly (cm 0 NA 0 15 0 25 below the costal margin) Hemoglobin level 9.7 NA 13.9 9,7 11 8,4 (g/dL) Platelet count 360 NA 220 360 180 214 ([mm.sup.3]) Leukocyte count 75.4 NA 67.7 160 69,7 123,7 ([mm.sup.3]) Blasts in PB (%) 1 NA 0 1 0 3 Sokal score Low NA Low Intermediate Low High Best cytogenetic PCR NA CCR NCR NCR NCR response Treatment HU, NA HU, HU, IFN, HU, HU, IFN, IFN, ARA-C, IM, GL IM, D IM I M D NA; Not Available; F: Female; M: Mate; PB: Peripheral Blood; HU: Hydroxyurea; INF: Interferon; ARA-C: Cytosine arabinoside; JM: Imatinib mesylate; D: Dasatinib; PCR: Partial cytogenetic response; CCR: Complete cytogenetic response; NCR: No cytogenetic response
Table 2. G-Banding and FISH results in the patients Patient Karyotype 1 46,XX,t(7;22)(p22;q11) 2 46, XY, t(9;22;15)(q34;q11;q22) 3 46, XY, t(13;15)(p11;q13), t(15;22)(p11;q11) 4 46,XX,t(9;22)(q34;q11)/46XX,t(1;9;22;3)(q24;q34;q11;q21) 5 46,XX,t(12;22)(p13;q11) 6 46, XY, t(4;8;9;22)(q11;q13;q34;q11) Patient Probe Hybridization pattern 1 BCR-ABL1 D-FISH BCR-ABL (+) 2 WCP 15 and 22 confirmed 3 BCR-ABL1 D-FISH BCR-ABL (+) 4 BCR-ABL1 D-FISH WCP 1, 9, BCR-ABL (+), 22 confirmed 5 BCR-ABL1 D-FISH BCR-ABL (+) 6 BCR-ABL1 D-FISH WCP 4, 8, BCR-ABL (+), BCR-ABL confirmed 9
Table 3. Chromosomes involved in variant Ph translocations in the 6 patients and previously reported breakpoints Chromosomes Type of translocations reported in the Reference seen in our literature cases 4pl4, 14q32 t(4;14;9;22)(pl4;q32;q34;qll) Aoun et al. 2004  6q25, 8q22 t(6;8;9;22)(q25;q22;q34;qll) Acar et al. 1997  1p36 t(l;9;22)(p36;q34;qll) 3p25 t(3;9;22)(p25;q34;qll) Yehuda et al. 1999  4pl4 t(4;9;22)(pl4;q34;qll) 12q22 t(9;22;12)(q34;qll;q22) 7q22 t(7;9;22)(q22;q34;qll) Zagariaa et al. 2004  8ql2 t(8;9;22)(ql2;q34;qll) 3q26 t(3;9;22)(q26;q34;qll) 4pl4 t(4;9;22)(pl4;q34;qll) Morel et al. 2003  4pl6 t(4;9;22)(pl6;q34;qll) 6p22, 12ql3 t(6,9;12;22)(p22;q34;ql3;qll) Zagariaa et al. 2006  lq36 t(l;22)(q36;qll) 4q31 t(4;9;22)(q31;q34;qll) 7ql2 t(7;9;22)(q31;q34;ql2) Zang et al. 1993  12q24.1 t(9;22;12)(q34;qll;q24.1) 3q26.2, 17q21 t(3;17;9;22)(q26.2;q21;q34;qll) 1p36 der(l)t(l;9;22)(p36.1;q34;ql1.2) 1q42 t(l;9;22)(q42;q34;qll.2) 7qll.2 der(9;22;7)ins(7;22)(q11.2;q 11q.12) Reddy et al. t(9;22;7)(q34;qll.2;qll.2) 2000  12P13 t(9;22;12)(q34;11.2;P13) 15q15, t(9;22;15;21)(q34;qll.2;ql5;qll.2) 21q11.2 1q25, 20ql3, t(l;20;9;22;l)(q25;ql3;q34;qll.2;p35) 1p35 1p36 t(l;9;22)(p36.1;q34;qll.2) 1q21 t(l;9;22)(q21;q34;qll.2) 12P13 t(9;22;12)(q34;qll.2;P13) Costa et al. 2006  12ql3 t(9;22;12)(q34;qll.2;ql3) 12pl3, 20ql2 t(9;22;20;12)(q34;qll.2;ql2;pl3) 1p36 t(l;9;22)(p36;q34;qll) 3p11 t(3;9;22)(pll;q34;qll) Markovic et al. 2000  3q12 t(3;9;22)(ql2;q34;qll) 4q12 t(4;9;22)(ql2;q34;qll) 1p36,11p15q23 t(l;ll;22)(p36.2;pl5ql3;ql2), Babicka et al. 2006  4q34 t(4;9;22)(q34;q34;qll) 1p36 t(l;9;22)(p36;q34;qll) 1q32 t(l;9;22)(q32;q34;qll) 1q42 t(l;9;22)(q42;q34;qll) 3p21 t(3;9;22)(p21;q34;qll) 3q21 t(3;22)(q21;qll) 4pl4 t(4;9;22)(P14;q34;qll) 4pl6 t(4;22)(pl6;qll) 4q31 t(4;9;22)(q31;q34;qll) 7q11 t(7;9;22)(qll;q34;qll) 7q32 t(7,9,22)(q32;q34;qll) Reid et al. 2003  12p12 t(12;22)(pl2;qll) 12q13 t(9;22;12)(q34;qn;ql3) 12ql4 t(9;22;12)(q34;qll;ql4) 15q15 t(9;22;15)(q34;qll;ql5) 15q15 t(l5;22)(ql5;qll) 15q24 t(9;22;15)(q34;qll;q24) 5q13,7q11 t(5;7;9;22)(ql3;qll;q34;qll) 6q24, 8q24 t(6;9;22;8)(q24;q34;qll;q24) 7q22,15q14 t(7;9;22;l5)(q22;q34;qll;ql4) 4q12 t(4;22)(ql2;qll) Baxter et al. 2002  4q25 t(4;9;22)(q25;q34;qll) Sheth et al. 2005  Note. The same breakpoints with ours that involved in variant Ph translocations in literature were marked by bold character
|Gale Copyright:||Copyright 2011 Gale, Cengage Learning. All rights reserved.|